DBV Technologies Reveals Stronger Phase 3 Peanut Allergy Data, Confirms H1 2026 BLA Submission
Summary
DBV Technologies presented additional positive data from its Phase 3 VITESSE study for the VIASKIN® Peanut Patch, showing significant desensitization in children and confirming plans for a Biologics License Application (BLA) submission in the first half of 2026.
Key Events
-
Additional Positive Phase 3 Data
New data from the VITESSE study showed 82.8% of children treated with VIASKIN® Peanut Patch increased their eliciting dose at month 12, compared to 48% in the placebo group.
-
Significant Desensitization Observed
60.1% of treated children increased their eliciting dose by at least two doses, while only 6.4% saw a decrease, compared to 24% in the placebo group.
-
BLA Submission Confirmed
The company reiterated its plan to submit a Biologics License Application (BLA) for the VIASKIN® Peanut Patch to the FDA in the first half of 2026.
Analysis
This 8-K highlights robust additional data from the successful Phase 3 VITESSE study, reinforcing the efficacy and safety profile of the VIASKIN® Peanut Patch for peanut-allergic children. The detailed results, showing a high percentage of children increasing their eliciting dose and a low percentage experiencing decreased tolerance, strengthen the product's clinical profile. The explicit confirmation of a Biologics License Application (BLA) submission to the FDA in the first half of 2026 provides a clear regulatory timeline, which is a critical de-risking event for a late-stage biopharmaceutical company. This positive development could significantly advance the company's path to commercialization and address a substantial unmet medical need.
At the time of this filing, DBVT was trading at $21.28 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.2B. The 52-week trading range was $3.82 to $26.19. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.